Sign inJoin waitlistJoin the waitlist

Vinod Balachandran

Director, The Olayan Center for Cancer Vaccines at MSK · New York Presbyterian Hospital

Credentials: · · · ·

History

The Olayan Center for Cancer Vaccines at MSK · New York Presbyterian Hospital
Present
Director · New York Presbyterian Hospital
Present
New York Presbyterian Hospital
Present

Complex General Surgical Oncology
Memorial Sloan Kettering Cancer Center
2011–2013
Surgery
New York Presbyterian Hospital
2006–2011
Ph.D Biomedicine, University of Barcelona; B.S. Biotechnology, Autonomous University of Barcelona
Renaissance School of Medicine at Stony Brook University
2002–2006
B.S. Molecular Biophysics and Biochemistry, Yale University; M.D. University of California San Diego
1998–2002

Research

Nomograms in oncology: more than meets the eye
Review · The Lancet Oncology · 2015 · First of 4 authors · Corresponding · 2,821 citations
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer
Nature · 2023 · 1,126 citations
Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers
Cell · 2020 · 1,025 citations

WJ
William Jarnagin
154 papers
MD
Michael D'Angelica
147 papers
PK
Peter Kingham
138 papers
JD
Jeffrey Drebin
109 papers
AW
Alice Wei
89 papers
KS
Kevin Soares
78 papers · 4 as a fellow
Peter Allen
63 papers · 7 as a resident
Ronald DeMatteo
56 papers
NK
Nancy Kemeny
39 papers
EO
Eileen O'Reilly
36 papers
AC
Andrea Cercek
35 papers
JH
James Harding
26 papers

Grants

Group 2 Innate Lymphoid Cell Regulation of Pancreatic Cancer Immunity
National Cancer Institute · R01
Contact PI · $2.8M · Sloan-Kettering Inst Can Research
2022–2027
The Memorial Sloan Kettering Cancer Center SPORE in Pancreas Cancer
National Cancer Institute · P50
Project lead · $2.8M · Sloan-Kettering Inst Can Research
2022–2027
Defining Neoantigen Immunodominance for Antigen Selection and Biomarker Discovery in Human Pancreatic Cancer Immunotherapy
National Cancer Institute · U01
Contact PI · $3.1M · Sloan-Kettering Inst Can Research
2017–2022

Clinical trials

Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery
Principal investigator · Active not recruiting · Phase 1
Memorial Sloan Kettering Cancer Center
2019–2026